BTIG analyst Marie Thibault notes that Bloomberg reported that Shockwave Medical (SWAV) is attracting takeover interest from Boston Scientific (BSX). Such a deal, if it were to occur, would represent the largest acquisition for Boston in recent history, says the firm, which thinks there could be potential antitrust risk given Boston’s portfolio of existing rotational atherectomy systems. However, a potential deal for Shockwave would boost its portfolio of cardiovascular devices and "makes strategic sense to us" as such a potential acquisition would likely be accretive to revenue and margin growth, sayd BTIG. Such a deal would also "be a formidable response" to Abbott’s (ABT) pending acquisition of Cardiovascular Systems (CSII), the firm added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BSX:
- Shockwave Medical’s Rumored Takeover Sends It Climbing
- Boston Scientific put volume heavy and directionally bearish
- Boston Scientific exploring deal to acquire ShockWave, Bloomberg reports
- Needham med tech analysts to hold an analyst/industry conference call
- Boston Scientific price target raised to $56 from $52 at Mizuho